Although ECHELON-2 was not powered to directly compare BV + CHP vs. CHOP among non-ALCL subgroups, responses trending towards superiority were observed in the major PTCL subtypes (despite wide confidence intervals) and were statistically significant in both ALK-positive and ALK-negative ALCL [25]. This evidence concerns the gene ALK and mature T-cell and NK-cell non-Hodgkin lymphoma.